Back to School: How biopharma can reboot drug development. Access exclusive analysis here

YM raises $9.8 million

Cancer therapeutics developer YM BioSciences (LSE:YMB; TSE:YM.PR.B) raised

Read the full 81 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE